The predictive value of ERCC1 and p53 for the effect of panobinostat and cisplatin combination treatment in NSCLC.
about
Establishment of a first‑line second‑line treatment model for human pulmonary adenocarcinomaPlatinum Concentration and Pathologic Response to Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder CancerCombination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions.DNA Repair Genes ERCC1 and BRCA1 Expression in Non-Small Cell Lung Cancer Chemotherapy Drug Resistance.TR4 nuclear receptor enhances the cisplatin chemo-sensitivity via altering the ATF3 expression to better suppress HCC cell growth.Trp53 Mutants Drive Neuroendocrine Lung Cancer through Loss-of-Function Mechanisms with Gain-of-Function Effects on Chemotherapy Response.CUDC-907, a dual HDAC and PI3K inhibitor, reverses platinum drug resistance.Synthesis, Fluorescence Properties, and Antiproliferative Potential of Several 3-Oxo-3H-benzo[f]chromene-2-carboxylic Acid Derivatives.18F-fludrodeoxyglucose maximal standardized uptake value and metabolic tumor burden are associated with major chemotherapy-related tumor markers in NSCLC patients.Panobinostat sensitizes KRAS-mutant non-small-cell lung cancer to gefitinib by targeting TAZ.Synergistic anticancer effect of panobinostat and topoisomerase inhibitors through ROS generation and intrinsic apoptotic pathway induction in cervical cancer cells.
P2860
Q28468342-73024807-6EC9-45F1-98B2-735F19F91A73Q28552143-15CE21FD-748C-4BF7-87A5-5174858B10A9Q33798999-4978895C-6E15-45C6-8B4E-61577DE16DE1Q37020946-F09C3BCB-329E-4DBA-9CB4-B24D3E4D05FEQ37362609-C326A54B-7A65-490D-857C-621CE062EFEDQ38605143-8D935FE4-5EEE-4AD4-B6CC-DA54A414BEFAQ38618905-268F832A-0CA6-441E-99A6-F3EE60F8DA36Q38827443-B4420282-5168-43D7-93EF-E86C78F0C072Q41518218-B9A27C0F-3838-4283-B1F7-B33F16AD0884Q48121325-559B60A7-5E88-4690-A36E-673E9321F331Q52739228-9D362C57-4EC9-426A-B66E-1F9ABE367F6D
P2860
The predictive value of ERCC1 and p53 for the effect of panobinostat and cisplatin combination treatment in NSCLC.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
The predictive value of ERCC1 ...... ombination treatment in NSCLC.
@en
type
label
The predictive value of ERCC1 ...... ombination treatment in NSCLC.
@en
prefLabel
The predictive value of ERCC1 ...... ombination treatment in NSCLC.
@en
P2093
P2860
P356
P1433
P1476
The predictive value of ERCC1 ...... ombination treatment in NSCLC.
@en
P2093
Guoqing Zhang
Weihong Zhao
P2860
P304
18997-19005
P356
10.18632/ONCOTARGET.3620
P407
P577
2015-04-29T00:00:00Z